Literature DB >> 22258485

Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.

Xavier Mariette1, Gabriel Baron, Florence Tubach, Frédéric Lioté, Bernard Combe, Corinne Miceli-Richard, René-Marc Flipo, Philippe Goupille, Matthieu Allez, Dominique Salmon, Dominique Emilie, Guislaine Carcelain, Philippe Ravaud.   

Abstract

BACKGROUND: The recommendations for detecting latent tuberculosis infection (LTBI) before antitumour necrosis factor (anti-TNF) therapy are based on the tuberculin skin test (TST), which lacks both specificity and sensitivity and can lead to unnecessary treatment with antibiotics. A study was undertaken to investigate the effect of replacing TST with interferon γ (IFNγ) release assays (IGRA) in screening for LTBI and deciding to begin prophylactic antituberculosis (TB) antibiotics before anti-TNF therapy in immune-mediated inflammatory diseases.
METHODS: In 15 tertiary care hospitals, consecutive patients with rheumatoid arthritis, spondylarthropathies or Crohn's disease were screened for LTBI before anti-TNF therapy with TST, QuantiFERON TB Gold in tube (QTF-Gold IT) and T-SPOT.TB at the same time. The potential diagnosis of LTBI and the effect on the decision to begin antibiotic prophylaxis were assessed.
RESULTS: Among 429 patients, 392 had results for the three tests. The results for TST, T-SPOT.TB and QTF Gold IT were positive for 35.2%, 15.1% and 9.9% of patients, respectively (p<0.0001). Antibiotics were required for 177 patients (45.2%) if positive TST results were included in the LTBI definition, 107 patients (27.3%) if TST results were replaced with results from one of the IGRA tests and 84 patients (21.4%) if TST results were replaced with QTF-Gold IT results (p<0.0001). The decision on the use of antibiotic prophylaxis was changed for 113 patients (28.8%, 95% CI 24.4% to 33.6%) if TST results were replaced with QTF-Gold IT results.
CONCLUSIONS: Replacing TST with IGRA for determining LTBI allowed the proportion of patients with immune-mediated inflammatory diseases needing prophylactic anti-TB antibiotics before beginning anti-TNF agents to be reduced by half.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258485     DOI: 10.1136/annrheumdis-2011-200408

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  24 in total

Review 1.  Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.

Authors:  Kevin L Winthrop; Michael Iseman
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

2.  [Are the recommendations on tuberculosis screening still valid? Interferon gamma release assay (IGRA) and/or tuberculin skin test for diagnosis of latent tuberculosis infection (LTBI)].

Authors:  D Ernst; T Witte; R E Schmidt; D Meyer-Olson
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

3.  Specificity of QuantiFERON-TB Plus, a New-Generation Interferon Gamma Release Assay.

Authors:  S A R Siegel; M Cavanaugh; J H Ku; L M Kawamura; K L Winthrop
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

4.  [Clinical presentation of tuberculosis in routine practice].

Authors:  R Dinser; M Frerix; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2012-10       Impact factor: 1.372

5.  Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.

Authors:  Patricio Escalante; Kirstin J Kooda; Rizwana Khan; San San Aye; Stratos Christianakis; Daniel G Arkfeld; Glenn R Ehresmann; Jens J Kort; Brenda E Jones
Journal:  Lung       Date:  2014-10-16       Impact factor: 2.584

6.  IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?

Authors:  Juan González-Moreno; Mercedes García-Gasalla; Inés Losada-López; Carmen Cifuentes Luna; Isabel Mir Viladrich; Victoria Fernández-Baca; Araceli Serrano; Antonio Juan Mas; Joan Riera-Oliver; Antoni Payeras Cifre
Journal:  Rheumatol Int       Date:  2017-10-19       Impact factor: 2.631

Review 7.  Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis.

Authors:  Qiaoling Ruan; Shu Zhang; Jingwen Ai; Lingyun Shao; Wenhong Zhang
Journal:  Clin Rheumatol       Date:  2014-11-07       Impact factor: 2.980

8.  QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results.

Authors:  Emrah Seyhoglu; Oğuz Abdullah Uyaroğlu; Abdulsamet Erden; Levent Kilic; Omer Karadag; Ali Akdogan; Sule Apras Bilgen; Ihsan Ertenli; Sedat Kiraz; Umut Kalyoncu
Journal:  Clin Rheumatol       Date:  2020-10-15       Impact factor: 2.980

9.  [Prophylaxis and treatment of infections in elderly patients with rheumatism].

Authors:  C Kneitz; A Strangfeld; K Krüger
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

Review 10.  Diagnosis and Management of Latent Tuberculosis Infection.

Authors:  Laura Muñoz; Helen R Stagg; Ibrahim Abubakar
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-08       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.